Population characteristics. Data presented as n (%) except as otherwise indicated.
| SpA, n = 85 | SpA-FM, n = 18 | p* | axSpA, n = 69 | axSpA-FM, n = 12 | p* | |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age, yrs, median (IQR) | 41.9 (20.8) | 46.4 (22.9) | 0.3550 | 40.9 (17.7) | 44.6 (23.0) | 0.5995 |
| Women | 25 (29.4) | 12 (66.7) | 0.0056 | 18 (26.1) | 6 (50.0) | 0.1669 |
| Weight, kg, median (IQR) | 75 (23) | 69.5 (23.6) | 0.2323 | 75 (21.5) | 73.2 (22.7) | 0.8680 |
| Height, cm, median (IQR) | 172 (14) | 163.5 (11.4) | 0.0102 | 172 (12.5) | 165.5 (13) | 0.2085 |
| BMI, kg/m2, median (IQR) | 25.6 (5.7) | 25.4 (4.6) | 0.8758 | 25.6 (5.7) | 25.6 (7.1) | 0.6851 |
| Married | 55 (64.7) | 13 (72.2) | 0.5970 | 45 (65.2) | 8 (66.7) | 1 |
| Parent, n = 91 | 56/74 (75.7) | 13/17 (76.5) | 1 | 46/61 (75.4) | 7/11 (63.6) | 0.4651 |
| City dweller | 51 (60.0) | 11 (61.1) | 1 | 44 (63.7) | 8 (66.6) | 1 |
| Active worker, n = 102 | 58/85 (68.2) | 11/17 (64.7) | 0.7820 | 48/69 (69.6) | 9/12 (75) | 1 |
| SpA profile | ||||||
| Disease duration, yrs (n = 102), median (IQR) | 10.5 (13.8) | 9.5 (10.8) | 0.7819 | 11 (13) | 6.5 (9) | 0.3214 |
| axSpA (ASAS) | 69 (81.2) | 12 (66.7) | 0.2073 | |||
| Radiographic, n = 78 | 50/66 (75.7) | 5/12 (41.7) | 0.0341 | |||
| Peripheral manifestations | 45 (52.9) | 12 (66.7) | 0.3117 | 29 (42.0) | 6 (50.0) | 0.7543 |
| Arthritis | 39 (45.9) | 9 (50.0) | 0.7990 | 24 (34.8) | 3 (25.0) | 0.7418 |
| Enthesitis | 9 (10.6) | 4 (22.2) | 0.2352 | 7 (10.1) | 3 (25.0) | 0.1631 |
| Dactylitis | 6 (7.1) | 2 (11.1) | 0.6263 | 4 (5.8) | 1 (8.3) | 0.5614 |
| Psoriasis | 29 (34.1) | 4 (22.2) | 0.4119 | 16 (23.2) | 2 (16.7) | 1 |
| IBD | 3 (3.5) | 1 (5.6) | 0.5420 | 2 (2.9) | 0 (0.0) | 1 |
| Uveitis | 17 (20.0) | 1 (5.6) | 0.1864 | 17 (24.6) | 1 (8.3) | 0.2829 |
| Prosthesis | 7 (8.2) | 2 (11.1) | 0.6548 | 6 (8.69) | 2 (16.7) | 0.3375 |
| HLA-B27, n = 98 | 53/81 (65.4) | 13/17 (76.5) | 0.5703 | 51/67 (76.1) | 10/12 (83.3) | 0.7237 |
| CRP, mg/l, n = 99, median (IQR) | 4 (7.0) | 3.5 (8.8) | 0.8646 | 4 (7.5) | 2 (8) | 0.5612 |
| Treatment | ||||||
| No. drugs, median (IQR) | 2 (2) | 2 (4.5) | 0.9574 | 2 (3) | 2 (2.75) | 0.5041 |
| NSAID | 46 (54.1) | 8 (44.4) | 0.6045 | 39 (56.5) | 12 (41.7) | 0.3663 |
| Corticosteroid | 2 (2.4) | 1 (5.6) | 0.4415 | 2 (2.9) | 1 (8.3) | 0.3859 |
| DMARD | 29 (34.1) | 3 (16.7) | 0.1725 | 17 (24.6) | 0 (0) | 0.0619 |
| Anti-TNF | 26 (30.6) | 3 (16.7) | 0.3865 | 24 (34.8) | 2 (16.7) | 0.3201 |
| Analgesics | 23 (27.1) | 7 (38.9) | 0.3927 | 21 (30.4) | 12 (33.3) | 1 |
| Hypnotic | 3 (3.5) | 3 (16.7) | 0.0645 | 3 (4.3) | 2 (16.7) | 0.1565 |
| Antidepressant drugs | 4 (4.7) | 2 (11.1) | 0.2812 | 4 (5.8) | 1 (8.3) | 0.5614 |
↵* Mann-Whitney or Fisher’s exact test as appropriate; p < 0.05 considered significant. When missing values occurred, the total number of available data for the item is indicated in brackets in column 1, and the number of missing values was then excluded from the denominator for percentage calculation for each variable concerned. SpA: spondyloarthritis; axSpA: axial SpA; FM: fibromyalgia; IQR: interquartile range; BMI: body mass index; IBD: inflammatory bowel disease; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs; analgesics: acetaminophen or morphine derivatives; ASAS: Assessment of SpondyloArthritis International Society; CRP: C-reactive protein; TNF: tumor necrosis factor.